Wedbush initiated coverage of Cartesian Therapeutics (RNAC) with an Outperform rating and $38 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAC:
- Cartesian Therapeutics Holds Annual Stockholders Meeting
- Cartesian Therapeutics announces employment inducement grants
- Promising Outlook for Cartesian Therapeutics: Buy Rating Backed by Advancements in Descartes-08 Trials and Strong Financial Projections
- Cartesian announces first participant enrolled in Phase 3 AURORA trial
- Cartesian selloff brings ‘attractive buying opportunity,’ says Mizuho